3 results
The objective of this phase-3 randomized study, with a double-blind treatment period of 8 weeksduration is to evaluate the efficacy and safety of the fixed dose combinations of TAK-491 pluschlorthalidone (40/12.5 mg and 40/25 mg) in subjects with…
The main objective is to evaluate the average time span within which *time of onset* and *time of offset* occurs in patients with overactive bladder syndrome or non-obstructive urinary retention who respond to SNM.
The primary objective is to investigate if IMO-2125 is capable of a) lowering the number of tumor positive SLN and b) inducing a loco-regional and systemic immune response. The secondary objective is to investigate RFS and OS at 18 months, 24 months…